This past Thursday, NeoGenomics, Inc. (NASDAQ: NEO) was involved in strange option trading activity. The total number of call options for the stock purchased by investors was 5,070. This represents an increase of 1,203 percent compared to the typical volume of 389 call options.
The number of shares of NEO stock that changed hands at midday trading on Thursday was 34,510, a significant decrease from the average turnover of 1,698,902 shares that took place during this time. The company’s simple moving average price over the past 50 days is $9.26, and the company’s simple moving average price over the last 200 days is $9.36. During the previous year, the price of NeoGenomics ranged from a low of $6.00 to a high of $35.40. The company’s market capitalization is 1.36 billion dollars, and it has a price-to-earnings ratio of -8.14 and a beta of 1.01. The debt-to-equity ratio is 0.53, and the quick, current, and current ratios are 6.82. The debt-to-equity ratio is an important measure of financial health. The debt-to-equity ratio is essential to a company’s overall financial health.
Researchers with expertise in various disciplines have discussed the organization and offered their points of view. In a research report that Piper Sandler distributed on November 14th, the target price for NeoGenomics’ stock was decreased from $19.00 to $18.00. This change came as a result of the report. In addition, this study gave an “overweight” rating to the company’s stock. SVB Leerink increased the price target for NeoGenomics on November 9th from $10.00 to $15.00, and the company also gave the stock an “outperform” rating. The research report was issued in conjunction with the publication of the report. Needham & Company LLC changed their recommendation for NeoGenomics in a research report published on Monday, August 22nd. Previously, they had rated the company as a “buy,” but now they rate it as a “hold.” The price objective that Morgan Stanley has set for NeoGenomics has been reduced from $18.00 to $17.00, as stated in a research note that was made public on November 9th. At the time, the company also bestowed a rating of “equal weight” on NeoGenomics. In a research note published on October 28th, William Blair reaffirmed its “outperform” rating on shares of NeoGenomics. After having previously given this rating, the company has now given it again. Six equity research experts have recommended that investors keep their current positions, while the remaining six have given the stock a buy rating. One of the equity research experts has suggested that investors sell the stock. Information obtained from Bloomberg.com indicates that the current average rating for NeoGenomics is “Hold,” and the website users have set the price objective for the company at $19.00. This information was obtained from the website.
Recent transactions have resulted in several institutional investors and hedge funds modifying the number of shares of the company’s stock they already owned. During the second quarter of the fiscal year, Ronald Blue Trust Inc. made a total investment of $28,000 in NeoGenomics, which is considered a new investment. During the third quarter, Quadrant Capital Group LLC made a 149.5% increase in the amount of NeoGenomics stock it owned, bringing its total percentage to 100%. After making an additional purchase of 1,814 shares during the most recent reporting period, Quadrant Capital Group LLC now holds 3,027 shares of the medical research company’s stock, which is $26,000. This brings the total number of shares owned by the company to 3,027. Over the first three months of the year, Captrust Financial Advisors saw a 404.7% increase in the value of their holdings in NeoGenomics. Captrust Financial Advisors now has a total of 4,936 shares of the medical research company’s stock, which has a market value of $60,000. This is because, during the most recent quarter of the company’s fiscal year, Captrust Financial Advisors purchased an additional 3,958 shares. NeoGenomics received a financial contribution of $44,000 from the Security Benefit Life Insurance Co. of Kansas during the second quarter. And finally, during the second quarter, Strs Ohio increased its holdings in NeoGenomics by 450.0 percent. The most recent fiscal quarter saw Strs Ohio acquire an additional 5,400 shares, bringing the total number of shares owned in the medical research business to 6,600, with a value of $53,000 for those 6,600 shares. The company’s shares are held collectively by hedge funds and other types of institutional investors to the extent of 92.75 percent.
The management of a network of cancer testing labs that extends across the continents of Asia, Europe, and North America is the responsibility of NeoGenomics, Inc. Pharma Services and Clinical Services are the names of the company’s two primary business divisions, respectively. Pathologists, oncologists, physicians, pharmaceutical companies, and researchers can benefit from the company’s testing services, which are beneficial to institutions such as hospitals and reference labs. Researchers can also benefit from the company’s testing services.
Discussion about this post